TROAP and cancer: While it was found to be pro-tumorigenic and associated with poor prognosis in most cancer types, including glioma, lung, breast, ovarian, colorectal, gastric and prostate cancer (Li K. et al., 2019; Jin et al., 2020; Zhao et al., 2021; Liu H. et al., 2022; Li et al., 2022; Wang et al., 2023; Yue et al., 2023), some studies suggest that high expression of TROAP could predict better survival in acute myeloid leukemia (He et al., 2023).